1 day Ago By ABMN Staff
Bank of New York Mellon Corp increased its stake in shares of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT – Free Report ) by 32.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 204,892 shares of the company’s stock after buying an additional 50,388 shares during the quarter. Bank of New York Mellon Corp owned about 0.39% of EyePoint Pharmaceuticals worth $1,783,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in EYPT. Ameritas Investment Partners Inc. lifted its stake in EyePoint Pharmaceuticals by 44.
0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after purchasing an additional 1,136 shares during the last quarter.
China Universal Asset Management Co. Ltd. raised its position in EyePoint Pharmaceuticals by 129.
9% during the 1st quarter. China Universal Asset Management Co. Ltd.
now owns 9,393 shares of the company’s stock worth $194,000 after purchasing an additional 5,308 shares during the last quarter. ProShare Advisors LLC bought a new position in EyePoint Pharmaceuticals during the 1st quarter worth $209,000. Capstone Investment Advisors LLC bought a new position in EyePoint Pharmaceuticals during the 1st quarter worth $230,000.
Finally, Virtu Financial LLC bought a new position in EyePoint Pharmaceuticals during the 1st quarter worth $241,000. Institutional investors and hedge funds own 99.41% of the company’s stock.
Analyst Ratings Changes A number of analysts have weighed in on the company. Jefferies Financial Group assumed coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.
00 price target for the company. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price target on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th.
StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Thursday, September 5th. HC Wainwright reissued a “buy” rating and set a $30.
00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. dropped their target price on shares of EyePoint Pharmaceuticals from $32.
00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company.
According to data from MarketBeat.com, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $30.57.
EyePoint Pharmaceuticals Trading Up 1.5 % NASDAQ:EYPT opened at $8.91 on Thursday.
The stock has a market capitalization of $476.86 million, a PE ratio of -5.12 and a beta of 1.
59. The firm’s 50 day moving average is $8.89 and its 200 day moving average is $13.
09. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.
67 and a 12 month high of $30.99. EyePoint Pharmaceuticals ( NASDAQ:EYPT – Get Free Report ) last released its quarterly earnings data on Wednesday, August 7th.
The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.
03). EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.
24%. The business had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $11.
61 million. Research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.
33 earnings per share for the current year. Insider Activity at EyePoint Pharmaceuticals In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Friday, July 12th.
The shares were sold at an average price of $10.06, for a total value of $116,947.50.
Following the completion of the transaction, the director now directly owns 1,850 shares in the company, valued at approximately $18,611. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . 4.
74% of the stock is owned by company insiders. EyePoint Pharmaceuticals Company Profile ( Free Report ) EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Featured Articles Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
